Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men

Internal Medicine

Volumn 47, Issue 13, 2008, Pages 1175-1180

  Tamba, Sachiko ^a   Nishizawa, Hitoshi ^a   Funahashi, Tohru ^a   Okauchi, Yukiyoshi ^a   Ogawa, Tomoki ^b   Noguchi, Midori ^b   Fujita, Koichi ^a   Ryo, Miwa ^a   Kihara, Shinji ^a   Iwahashi, Hiromi ^a   Yamagata, Kazuya ^a   Nakamura, Tadashi ^a   Shimomura, Iichiro ^a   Matsuzawa, Yuji ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b General Affairs Bureau   (Japan)

^c SUMITOMO HOSPITAL   (Japan)

Author keywords

Adiponectin; Bioelectrical impedance analysis method; Metabolic syndrome; Uric acid; Visceral fat accumulation

Indexed keywords

ADIPONECTIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; URIC ACID;

ADULT; ARTICLE; BODY MASS; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERURICEMIA; INTRAABDOMINAL FAT; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; JAPAN; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADIPONECTIN; ADULT; AGED; HUMANS; HYPERURICEMIA; INTRA-ABDOMINAL FAT; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 49649096922     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0603     Document Type: Article

References (42)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365: 1415-1428, 2005.
2. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
3. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54: 254-260, 1982.
4. Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life in people with large circumference. Lancet 351: 853-856, 1998.
5. Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239-246, 1994.
6. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the framingham Heart Study. Ann Intern Med 131: 7-13, 1999.
7. Verdecchia P, Schillaci. G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in, essential hypertension. The PIUMA study. Hypertension 36: 1072-1078, 2000.
8. The Committee for Japanese Definition of Metabolic Syndrome. Definition and criteria of metabolic syndrome. J Jpn Soc Int Med 94: 794-809, 2005 (in Japanese).
9. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106; 2767-2770, 2002.
10. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Me, 8: 731-737, 2002.
11. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
12. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730, 1737, 2004.
13. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-59, 2002.
14. Adamczak M, Wiecek A, Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16: 72-75, 2003.
15. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68: 975-981, 2004.
16. Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes 7: 437-445, 1983.
17. Ryo M, Maeda K, Onda T, et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 28: 451-453, 2005.
18. Japanese Society of Gout and Nucleic Acid Metabolism. Guidelines for the management of hyperuricemia and gout. Japanese Society of Gout and Nucleic Acid Metabolism, Tokyo, 2002 (in Japanese).
19. http://www.mhlw.go.jp/houdou/2006/05/h0508-1a.html (5 May, 2006) (in Japanese).
20. Kawamoto R, Tomita H, Oka Y, Obtsuka N. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intem Med 45: 605-614, 2006.
21. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentraoon and insulin resistance and metabolic syndrome. Circ J 69: 928-933, 2005.
22. Onat A, Uyarel H, Hergene G, et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19: 1055-1062, 2006.
23. Becker MA, Smith PR, Taylor W, Mustafi R, Switzer RL. The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest 96: 2133-2141, 1995.
24. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake and the risk of gout in men N Engl J Med 350: 1093-1103, 2004.
25. Liberopoulos EN, Miltladous GA, Elisaf MS, Alcohol intake, serum uric acid concentrations, and risk of gout. Lancet 364: 246-247, 2004.
26. Anumonye A, Bobson JW, Oppenheim S, Sutherland JS, Plasma uric acid concentrations among Einburgh business executives. JAMA 208: 1141-1144, 1969.
27. Sutton JR, Toews CJ, Ward GR, Fox IH. Purine metabolism during strenuous muscular exercise in man. Metabolism 29: 254-260, 1980.
28. Rathmann W, Haastert B, Icks A, Giani G, Roseman JM. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black acid white adults: the CARDIA study. Eur J Epidemiol 22: 439-445, 2007.
29. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF 2nd, Kullo, IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 20: 83-89, 2007.
30. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc 69: 512-516, 2006.
31. Hollister LE, Overall JE, Snow HL, et al. Relationship of obesity to serum triglyceride, cholesterol, and uric acid and to plasma-glucose levels. Am J Clin Nutr 20: 777-782, 1967.
32. Krizek V. Serum uric acid in relation to body weight. Ann Rheum, 25: 456-458, 1966.
33. Hikita M, Ohno I, Hosoya T, et al. Relationship between hyper-uricemia and body fat distribution. Intern Med 46: 1353-1358, 2007.
34. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 30: 616-634, 1981.
35. Fabregat I, Revilla E, Machado A. Short-term control of the pentose phosphate cycle by insulin could be modulated by NADPH/NADP ratio in rat adipocytes and hepatocytes. Biochem Biophys: Res Commun 146 920-925, 1987.
36. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric - acid concentration. JAMA 266: 3008-3011, 1991.
37. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 352: 670-671, 1998.
38. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality The NHANES I epidemiologic follow up study. JAMA 283: 2404-2440, 2000.
39. Johnson RJ, Kang DR, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183-1190, 2003.
40. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16: 3553-3562, 2005.
41. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 580: 2917-2921, 2006.
42. Okauchi Y, Nishizawa H, Funahashi T, et al. Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care 30: 2392-2394, 2007.